Jump to main content
Jump to site search

Issue 42, 2017
Previous Article Next Article

Clinical evaluation of the radiolanthanide terbium-152: first-in-human PET/CT with 152Tb-DOTATOC

Author affiliations

Abstract

The existence of theragnostic pairs of radionuclides allows the preparation of radiopharmaceuticals for diagnostic and therapeutic purposes. Radiolanthanides, such as 177Lu, are successfully used for therapeutic purposes; however, a perfect diagnostic match is currently not available for clinical use. A unique, multi-disciplinary study was performed using 152Tb (T1/2 = 17.5 h, Eβ+average = 1140 keV, Iβ+ = 20.3%), which resulted in the first-in-human PET/CT images with this promising radionuclide. For this purpose, 152Tb was produced via a spallation process followed by mass separation at ISOLDE, CERN. The chemical separation and quality control, performed at PSI, resulted in a pure product in sufficient yields. Clinical PET phantom studies revealed an increased image noise level, because of the smaller β+ branching ratio of 152Tb as compared to standard PET nuclides at matched activity concentrations; however, the expected recovery would be comparable at matched signal-to-noise ratios in clinical PET. 152Tb was used for labeling DOTATOC, at Zentralklinik Bad Berka, and administered to a patient for a first-in-human clinical study. PET scans were performed over a period of 24 h, allowing the visualization of even small metastases with increased tumor-to-background contrast over time. Based on the results obtained in this work, it can be deduced that PET/CT imaging with 152Tb-labeled targeting agents has promise for clinical application and may be particularly interesting for pre-therapeutic dosimetry.

Graphical abstract: Clinical evaluation of the radiolanthanide terbium-152: first-in-human PET/CT with 152Tb-DOTATOC

Back to tab navigation

Publication details

The article was received on 27 May 2017, accepted on 07 Aug 2017 and first published on 21 Aug 2017


Article type: Paper
DOI: 10.1039/C7DT01936J
Citation: Dalton Trans., 2017,46, 14638-14646
  •   Request permissions

    Clinical evaluation of the radiolanthanide terbium-152: first-in-human PET/CT with 152Tb-DOTATOC

    R. P. Baum, A. Singh, M. Benešová, C. Vermeulen, S. Gnesin, U. Köster, K. Johnston, D. Müller, S. Senftleben, H. R. Kulkarni, A. Türler, R. Schibli, J. O. Prior, N. P. van der Meulen and C. Müller, Dalton Trans., 2017, 46, 14638
    DOI: 10.1039/C7DT01936J

Search articles by author

Spotlight

Advertisements